The European Commission (EC) has granted marketing authorisation for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of relapsed or refractory follicular lymphoma. The combination regimen, developed by AbbVie and Genmab for the treatment of adult patients, is the first and only bispecific-based therapy approved in… Read More
Genmab has announced that the conditions to acquire all the issued and outstanding common shares of Merus for $97 per common share in cash have been satisfied. The company says the transaction diversifies its revenue and will drive sustained growth into the next decade. With… Read More
Genmab has agreed to acquire Merus, a clinical-stage biotechnology company with a late-stage breakthrough therapy asset called petosemtamab, which is in Phase III development. Genmab will pay $97.00 per share in an all-cash transaction representing a transaction value of approximately $8 billion. The proposed acquisition… Read More
The Japan Ministry of Health, Labour and Welfare has approved Genmab’s Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after chemotherapy treatment. Tivdak is the first antibody-drug conjugate (ADC) to be approved for people living with cervical cancer… Read More
AbbVie and Genmab’s Tepkinly (epcoritamab) has been granted conditional marketing authorisation by the European Commission (EC) as a monotherapy for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy. The approval makes Tepkinly the first subcutaneous T-cell engaging bispecific antibody… Read More
Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More
Genmab and AbbVie have announced updated data presented at ASH from the companies’ ongoing Phase I/II EPCORE NHL-1 clinical trial investigating epcoritamab (DuoBody CD3xCD20). Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously in 128 adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma… Read More
In the Phase III innovaTV 301 trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An independent data monitoring committee determined that OS crossed… Read More
The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines… Read More
